The Role of HER2 Status in the Biliary Tract Cancers

被引：10

作者：

Ayasun, Ruveyda ^{[1
]}

Ozer, Muhammet ^{[2
]}

Sahin, Ilyas ^{[3
]}

机构：

[1] NYU, Laura & Isaac Perlmutter Canc Ctr, Langone Med Ctr, New York, NY 10016 USA

[2] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02132 USA

[3] Univ Florida Hlth Canc Ctr, Dept Med, Div Hematol Oncol, Gainesville, FL 32608 USA

来源：

CANCERS | 2023年 / 15卷 / 09期

关键词：

biliary tract cancer; HER2; status; precision medicine; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; METASTATIC CHOLANGIOCARCINOMA; SINGLE-ARM; MULTICENTER; THERAPIES; PHASE-2; GEMCITABINE; FUTIBATINIB; MECHANISMS;

D O I：

10.3390/cancers15092628

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite recent advances, biliary tract cancer (BTC) is traditionally known as being hard to treat with a poor prognosis. Recent state-of-the-art genomic technologies such as next-generation sequencing (NGS) revolutionized cancer management and shed light on the genomic landscape of BTCs. There are ongoing clinical trials to assess the efficacy of HER2-blocking antibodies or drug conjugates in BTCs with HER2 amplifications. However, HER2 amplifications may not be the sole eligibility factor for these clinical trials. In this review, we aimed to comprehensively examine the role of somatic HER2 alterations and amplifications in patient stratification and provide an overview of the current state of ongoing clinical trials.

引用

页数：12

共 49 条

[1] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[2] PrognostA±c Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree [J].

Ata, Alper ;

Polat, Ayse ;

Serinsoz, Ebru ;

Sungur, Mehmet Ali ;

Arican, Ali .

PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (03) :831-838

[3]

Ayasun R, 2023, LANCET GASTROENTEROL, V8, P211, DOI [10.1016/S2468-1253(22)00402-2, 10.1016/s2468-1253(22)00402-2]

[4] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors [J].

Bahleda, R. ;

Meric-Bernstam, F. ;

Goyal, L. ;

Tran, B. ;

He, Y. ;

Yamamiya, I ;

Benhadji, K. A. ;

Matos, I ;

Arkenau, H-T .

ANNALS OF ONCOLOGY, 2020, 31 (10) :1405-1412

[5] Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1-Mediated Gemcitabine Chemoresistance [J].

Bai, Zhiqing ;

Guo, Zhiying ;

Liu, Jiaxing ;

Chen, Yu-Ann ;

Lu, Qian ;

Zhang, Ping ;

Hong, Lili ;

Wang, Yunfang ;

Dong, Jiahong .

FRONTIERS IN ONCOLOGY, 2022, 12

[6] Emerging role of precision medicine in biliary tract cancers [J].

Bogenberger, James M. ;

DeLeon, Thomas T. ;

Arora, Mansi ;

Ahn, Daniel H. ;

Borad, Mitesh J. .

NPJ PRECISION ONCOLOGY, 2018, 2

[7] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer [J].

Bose, Ron ;

Kavuri, Shyam M. ;

Searleman, Adam C. ;

Shen, Wei ;

Shen, Dong ;

Koboldt, Daniel C. ;

Monsey, John ;

Goel, Nicholas ;

Aronson, Adam B. ;

Li, Shunqiang ;

Ma, Cynthia X. ;

Ding, Li ;

Mardis, Elaine R. ;

Ellis, Matthew J. .

CANCER DISCOVERY, 2013, 3 (02) :224-237

[8] Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm [J].

Chakrabarti, Sakti ;

Kamgar, Mandana ;

Mahipal, Amit .

CANCERS, 2020, 12 (08) :1-21

[9] Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis [J].

Clements, Oliver ;

Eliahoo, Joseph ;

Kim, Jin Un ;

Taylor-Robinson, Simon D. ;

Khan, Shahid A. .

JOURNAL OF HEPATOLOGY, 2020, 72 (01) :95-103

[10] Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients [J].

de Bitter, Tessa J. J. ;

de Reuver, Philip R. ;

Lohman, Elise A. J. de Savornin ;

Kroeze, Leonie, I ;

Vink-Borger, Marianne E. ;

van Vliet, Shannon ;

Simmer, Femke ;

von Rhein, Daniel ;

Jansen, Erik A. M. ;

Verheij, Joanne ;

van Herpen, Carla M. L. ;

Nagtegaal, Iris D. ;

Ligtenberg, Marjolijn J. L. ;

van der Post, Rachel S. .

NPJ PRECISION ONCOLOGY, 2022, 6 (01)

← 1 2 3 4 5 →